Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Relieving spinal cord compression symptoms with a single radiation treatment

Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom
Relieving spinal cord compression symptoms with a single radiation treatment ( Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom )
4 Jun 2017

Halving duration of ADT for high risk prostate cancer patients

Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada
Halving duration of ADT for high risk prostate cancer patients ( Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada )
4 Jun 2017

Findings of a phase I/II study of nivolumab in patients with virus-associated tumours

Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France
Findings of a phase I/II study of nivolumab in patients with virus-associated tumours ( Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France )
4 Jun 2017

New personalised therapies for lung cancer

Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA
New personalised therapies for lung cancer ( Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA )
4 Jun 2017

Selumetinib in children with recurrent or refractory low-grade glioma

Dr Jason Fangusaro - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, USA
Selumetinib in children with recurrent or refractory low-grade glioma ( Dr Jason Fangusaro - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, USA )
4 Jun 2017

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain
Dose escalation results of ceritinib and nivolumab for ALK NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain )
4 Jun 2017

Tivantinib as second line therapy for high-MET HCC

Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy
Tivantinib as second line therapy for high-MET HCC ( Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy )
4 Jun 2017

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy

Prof Valentina Guarneri - Università degli Studi di Padova, Padua, Italy
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy ( Prof Valentina Guarneri - Università degli Studi di Padova, Padua, Italy )
4 Jun 2017

Global study sets new risk-based standard to personalise chemotherapy for colon cancer after surgery

Dr Axel Grothey - Mayo Clinic Cancer Centre, Rochester, USA
Global study sets new risk-based standard to personalise chemotherapy for colon cancer after surgery ( Dr Axel Grothey - Mayo Clinic Cancer Centre, Rochester, USA )
4 Jun 2017

Olaparib slows growth of BRCA-related metastatic breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA
Olaparib slows growth of BRCA-related metastatic breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )
4 Jun 2017

Web-based system for self-reporting symptoms may help patients live longer

Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of North Carolina, USA
Web-based system for self-reporting symptoms may help patients live longer ( Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of North Carolina, USA )
4 Jun 2017

3 or 6 months adjuvant oxaliplatin for colorectal cancer

Dr Tim Iveson - University Hospital Southampton, Salisbury, UK
3 or 6 months adjuvant oxaliplatin for colorectal cancer ( Dr Tim Iveson - University Hospital Southampton, Salisbury, UK )
4 Jun 2017